FDA approves Astellas’ Xospata for FLT3-mutated acute myeloid leukemia

FDA approves Astellas’ Xospata for FLT3-mutated acute myeloid leukemia

The drug is the second FLT3 inhibitor to win approval, after Novartis’ Rydapt in first-line disease. Daiichi Sankyo’s quizartinib could present competition if it wins approval, but it would target a somewhat narrower population of FLT3-mutated patients.

Source: https://ift.tt/2Quaeeg